MEI Pharma, Inc. (MEIP) News
Filter MEIP News Items
MEIP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest MEIP News From Around the Web
Below are the latest news stories about MEI PHARMA INC that investors may wish to consider to help them evaluate MEIP as an investment opportunity.
MEI Pharma Reports First Quarter Fiscal Year 2025 Cash PositionSAN DIEGO, November 12, 2024--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. |
MEI Pharma Reports Fiscal Year End 2024 Cash PositionSAN DIEGO, September 19, 2024--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024. |
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic AlternativesSAN DIEGO, August 12, 2024--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today announced that it has engaged Oppenheimer & Co. Inc. to serve as the Company’s exclusive financial advisor to assist in its previously announced process to review and evaluate strategic alternatives. The Company remains focused on maximizing the value of its assets for its stockholders. |
MEI Pharma to Consider Strategic AlternativesSAN DIEGO, July 22, 2024--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today announced that its Board of Directors has determined unanimously to begin evaluation of the Company’s strategic alternatives, including potential transactions as well as an orderly wind down of the Company, if appropriate, in order to maximize the value of its assets for its stockholders. The Company intends to evaluate and engage a financial advisor to assist in this process. |
7 Undervalued Biotech Stocks to Buy for Big-Time ReturnsEvery investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price. Of course, the broader healthcare ecosystem offers a compelling narrative for market participants. As the Covid-19 pandemic demonstrated, no matter how advanced we become as a society, a microscopic virus can impose devastation. In order to protect individuals and communities at large, enterprises need a way to address di |
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational HighlightsSAN DIEGO, May 09, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and nine months ended March 31, 2024, and highlighted recent corporate events. |
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344SAN DIEGO, April 11, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that the Company’s Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation for Phase 1 study. Additionall |
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer PatientsSAN DIEGO, April 11, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that 25% of evaluable patients with relapsed metastatic colorectal cancer ("mCRC") in Cohort 1 of the ongoing Phase 1b study evaluating ME-344, an investigational inhibitor of mitochondrial oxidative phosphorylation ("OXPHOS"), in combination with bevacizumab (Avastin®) had |
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology ForumSAN DIEGO, April 10, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16 at 1:30 PM Eastern Time. |
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid LeukemiaSAN DIEGO, March 26, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported initiation of enrollment in a 12-patient expansion cohort in the ongoing Phase 1 study evaluating voruciclib, an investigational selective oral cyclin-dependent kinase 9 ("CDK9") inhibitor, in combination with venetoclax (Venclexta®), a B-cell lymphoma 2 ("BCL2") inhibitor, |